Is telehealth allowed to prescribe Mounjaro in Florida?

If you’ve been considering GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight management, you might be wondering: Can I actually get these prescribed through telehealth? The short answer is yes—and for many people, it’s become the most convenient and accessible path to evidence-based weight loss treatment.

With telehealth adoption accelerating since 2020, millions of Americans now have access to prescription weight loss medications without leaving home. But navigating the rules—federal regulations, state-specific requirements, and provider qualifications—can feel overwhelming. This guide breaks down everything you need to know about getting weight loss medication through telehealth in 2025, including what’s legal, what’s safe, and how to find quality care.

Understanding Telehealth Prescribing: The Legal Landscape

Federal Rules: Why GLP-1 Medications Are Telehealth-Friendly

Here’s the crucial detail many people don’t realize: GLP-1 weight loss medications are not controlled substances. This distinction matters enormously for telehealth access.

Under federal law—specifically the Ryan Haight Act—controlled substances (like Adderall or certain pain medications) traditionally required an in-person examination before a doctor could prescribe them via telemedicine. During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) waived this requirement temporarily, and those flexibilities have been extended through December 31, 2025.

But medications like Wegovy (semaglutide 2.4mg), Ozempic (semaglutide 0.5-1mg), and Mounjaro (tirzepatide) were never subject to the Ryan Haight Act’s in-person rule because they’re unscheduled medications. This means that, at the federal level, there has never been a legal barrier to prescribing these drugs via telehealth—even before the pandemic.

Bottom line: Federal law fully supports telehealth prescribing of GLP-1 weight loss medications, as long as a valid patient-provider relationship is established (typically through a live video consultation with a licensed clinician).

State Regulations: Where Things Get More Complex

While federal law is clear, each state has its own medical practice regulations that govern telehealth. The good news? No state outright bans telehealth prescribing of weight loss medications. The variations come down to how you can access them.

Some states have embraced telehealth completely, allowing providers to evaluate, diagnose, and prescribe entirely through virtual visits. Others require certain safeguards—like an initial in-person examination or periodic check-ins—to ensure appropriate oversight of medications with significant metabolic effects.

States with the most telehealth-friendly policies include Washington, California, New York, and Illinois, where providers can establish a patient relationship and prescribe weight loss medications entirely through video consultations, with no mandatory in-person visits.

States requiring initial in-person exams include Arkansas, Georgia, Delaware, South Carolina, Texas, North Dakota, and Mississippi. In these states, you’ll typically need one physical examination (either before starting telehealth or within a specified timeframe after) to meet the state’s standard of care for prescribing anti-obesity medications.

States with comprehensive evaluation requirements like New Jersey and Virginia mandate not just a physical exam, but also laboratory work, documentation of diet and exercise plans, and regular follow-up visits. These requirements apply whether care is delivered in person or via telehealth—the key is that all elements of thorough evaluation must occur.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Who Can Prescribe Weight Loss Medications via Telehealth?

Medical Doctors and Doctors of Osteopathy

All 50 states allow licensed Medical Doctors (MDs) and Doctors of Osteopathy (DOs) to prescribe GLP-1 medications through telehealth, provided they’re licensed in the state where the patient is physically located during the consultation. This is the ‘gold standard’ pathway and typically has the fewest restrictions.

Nurse Practitioners (NPs)

Nurse Practitioners represent a growing share of telehealth providers, and their prescribing authority varies significantly by state:

Full Practice Authority (34 states + DC): In these states, NPs can evaluate patients and prescribe medications independently after meeting experience requirements (typically 2-3 years of supervised practice). States include Washington, Arizona, California, New York, Connecticut, Delaware, Utah, Virginia, and many others. This means NPs working with telehealth platforms can provide complete care without physician oversight.

Reduced/Restricted Practice (remaining states): In states like Texas, Florida, Georgia, Pennsylvania, and Mississippi, NPs must work under a collaborative agreement or supervisory arrangement with a physician. This doesn’t prevent them from prescribing GLP-1 medications via telehealth—it just means there’s a physician involved in their practice structure. For patients, this is largely invisible; you’ll still receive quality care from an experienced NP, but behind the scenes, there’s a supervising physician ensuring protocols are followed.

Notable 2025 development: Georgia recently passed legislation allowing NPs and PAs to prescribe certain controlled substances (like Schedule II medications) with physician delegation—a significant expansion of scope that reflects growing recognition of advanced practice providers’ capabilities. While this doesn’t directly affect GLP-1s (which aren’t controlled), it signals the trend toward broader prescriptive authority.

Physician Assistants (PAs)

Similar to NPs, Physician Assistants can prescribe weight loss medications in all states, but always under some level of physician collaboration or supervision. The specific arrangement varies by state, but PAs are valued members of telehealth teams and provide excellent care within their scope of practice.

At Klarity Health, we work exclusively with licensed, credentialed providers—whether MDs, DOs, NPs, or PAs—who are properly authorized to practice in your state. When you book a consultation, you can be confident your provider has met all legal and professional requirements to prescribe medications safely.

What to Expect: The Telehealth Weight Loss Consultation Process

If you’re new to telehealth for weight management, here’s what a typical consultation looks like:

Initial Evaluation (30-45 minutes)

Medical History Review: You’ll complete a comprehensive health questionnaire covering your weight history, previous weight loss attempts, current medications, allergies, and any chronic conditions (diabetes, high blood pressure, thyroid disorders, etc.).

Video Consultation: During your live video appointment, your provider will:

• Review your medical history in detail
• Discuss your weight loss goals and challenges
• Calculate your BMI (Body Mass Index) and assess clinical eligibility
• Screen for contraindications to GLP-1 therapy
• Explain how these medications work, expected outcomes, and potential side effects
• Develop a comprehensive treatment plan including lifestyle modifications

Clinical Criteria: To qualify for prescription GLP-1 medications, you generally need:

• BMI ≥30 (obesity), OR
• BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea, etc.)
• No contraindications (personal or family history of medullary thyroid carcinoma, pregnancy or plans to become pregnant, active pancreatitis, severe gastroparesis, or MEN2 syndrome)

Lab Work: Depending on your state and individual health status, your provider may order baseline lab tests—typically a comprehensive metabolic panel, A1C (if diabetes is a concern), and thyroid function tests. Some states like New Jersey and Virginia require lab work before prescribing; in others, it’s based on clinical judgment.

Prescription and Treatment Plan

If you’re a good candidate, your provider will send an electronic prescription to your preferred pharmacy. First prescriptions are often for a 4-week supply to assess tolerance and side effects. You’ll receive:

• Detailed medication instructions: How to store, prepare, and self-administer the injection
• Dosing schedule: GLP-1s typically start at a lower dose and gradually increase over weeks to months
• Lifestyle guidance: Nutrition recommendations, exercise goals, and behavioral strategies to support medication efficacy
• Side effect management: What to expect (nausea, constipation, decreased appetite) and when to contact your provider

Follow-Up Care

Responsible telehealth providers don’t just hand you a prescription and disappear. Expect:

Short-term follow-up (1-4 weeks): A check-in after starting medication to assess tolerance, address side effects, and ensure you’re comfortable with injections.

Ongoing monitoring (every 1-3 months): Regular visits to track weight loss progress, adjust dosing, review any concerns, and ensure the medication is working safely. Some states mandate specific follow-up intervals—Florida requires evaluation at least every 3 months, Virginia requires a 30-day check-in after starting therapy.

Long-term management: GLP-1 medications are intended for chronic use. You’ll need continued prescriptions and monitoring as long as treatment is appropriate. Your provider should regularly reassess whether the medication is still the right choice based on your weight loss progress and overall health.

State-Specific Considerations: Where You Live Matters

Let’s look at a few state examples to illustrate how rules vary:

California: Maximum Flexibility

California has been a telehealth leader for years. Providers can conduct the entire evaluation, prescribe, and manage follow-up care virtually. No in-person visit is required. NPs have full independent practice authority after gaining 3+ years of experience, meaning many telehealth platforms can offer care through NPs without physician oversight. California’s only special requirement for weight loss treatment is adhering to standard medical practice—thorough evaluation, appropriate indications, and documented informed consent.

Texas: Initial Exam Expected, Strict NP Oversight

Texas law generally expects an in-person physical examination as part of establishing a valid patient-physician relationship for prescriptive purposes, especially for medications with significant effects. While not an absolute ban on telehealth prescribing of GLP-1s, best practice in Texas is to have at least one in-person visit (or coordinate with a local provider for examination) before or shortly after beginning telehealth weight loss treatment.

Additionally, Texas has restrictive NP/PA rules: prescriptive authority requires a formal delegation agreement with a supervising physician. NPs and PAs cannot prescribe independently, even for non-controlled medications. Reputable Texas telehealth clinics structure their practices accordingly—you may see an NP for your consultation, but there’s always a supervising Texas-licensed physician overseeing the protocol.

New Jersey: Comprehensive Evaluation Mandate

New Jersey’s Board of Medical Examiners has explicit rules for prescribing weight-loss medications. Before any prescription, providers must conduct (or document):

• Complete medical and weight history
• Physical examination (may be done via high-quality video for telehealth, but must be thorough)
• Laboratory tests (metabolic panel, possibly EKG)
• Psychological screening (to identify eating disorders or contraindications)
• Personalized diet and exercise plan
• Informed consent discussing risks (including rare but serious side effects like pancreatitis, gallbladder disease, and thyroid tumors in animal studies)

These requirements make New Jersey one of the more rigorous states, but the intent is patient safety. Telehealth platforms serving New Jersey ensure all these elements are addressed—it just means your initial evaluation may be more extensive and might require coordinating lab work locally.

Florida: BMI Requirements and Regular Check-ins

Florida law specifies that weight-loss medications should only be prescribed to patients with BMI ≥30, and requires follow-up visits at least every 3 months during treatment. Telehealth is permitted, but the state wants ongoing oversight. Florida NPs have collaborative agreements with physicians (not full independence), so telehealth services must be structured accordingly. The 3-month follow-up rule is actually a good thing—it ensures you’re not abandoned after getting a prescription, which unfortunately happens with some less reputable online services.

Medication Overview: Wegovy, Ozempic, and Mounjaro

Wegovy (Semaglutide 2.4mg)

FDA Approval: Approved June 2021 specifically for chronic weight management in adults with obesity or overweight with comorbidities.

How it works: Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a naturally occurring hormone that regulates appetite and blood sugar. By activating GLP-1 receptors in the brain, it reduces hunger and increases feelings of fullness, leading to reduced calorie intake.

Dosing: Weekly subcutaneous injection, starting at 0.25mg and gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg.

Expected results: Clinical trials showed an average weight loss of 15% of body weight over 68 weeks when combined with lifestyle changes—significantly more effective than diet and exercise alone.

Telehealth considerations: Wegovy is fully appropriate for telehealth prescribing. Because it’s FDA-approved specifically for weight management (not just diabetes), there’s no ‘off-label’ discussion needed. However, the medication requires training on self-injection technique, which telehealth providers facilitate through video demonstration and written materials.

Cost and availability: As of 2025, Wegovy is widely available again after supply constraints in 2022-2023. Many insurance plans now cover it (though prior authorization may be required). Cash-pay costs typically range from $1,000-$1,500/month without insurance, though patient assistance programs and telehealth platforms sometimes offer more affordable options.

Ozempic (Semaglutide 0.5mg, 1mg, 2mg)

FDA Approval: Approved for type 2 diabetes management, NOT officially approved for weight loss.

The off-label reality: Ozempic contains the same active ingredient as Wegovy (semaglutide) but in doses intended for diabetes control. Many healthcare providers prescribe it ‘off-label’ for weight loss, especially when Wegovy was in short supply or when insurance doesn’t cover Wegovy but does cover Ozempic (for patients with diabetes).

Prescribing considerations: Off-label prescribing is legal and common in medicine, but responsible providers must:

• Document the medical rationale for using a diabetes medication for weight loss
• Obtain informed consent explaining it’s not FDA-approved for this indication
• Not prescribe it to patients with type 1 diabetes (contraindicated)
• Monitor appropriately for hypoglycemia if the patient isn’t diabetic

Telehealth prescribing: Perfectly legal via telehealth, with the same non-controlled status as Wegovy. However, some telehealth platforms focus on Wegovy or Mounjaro/Zepbound instead to avoid the off-label complications.

Mounjaro (Tirzepatide) / Zepbound

Dual approvals: Tirzepatide was first approved as Mounjaro for type 2 diabetes (May 2022), then approved as Zepbound for chronic weight management (November 2023).

How it works: Tirzepatide is a ‘twincretin’—it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action appears to produce even greater weight loss than semaglutide alone.

Dosing: Weekly injection, starting at 2.5mg and potentially titrating up to 15mg depending on response and tolerance.

Expected results: Clinical trials for Zepbound showed average weight loss of ~20% of body weight over 72 weeks—the most effective anti-obesity medication currently available.

Telehealth prescribing: Fully appropriate. For weight management, Zepbound is the officially approved brand. Mounjaro is sometimes prescribed off-label for weight loss (particularly for patients with prediabetes or metabolic syndrome), following the same off-label documentation standards as Ozempic.

Cost: Similar to Wegovy—$1,000-$1,500/month without insurance. Insurance coverage is expanding as payers recognize the long-term health benefits and cost savings from treating obesity.

Red Flags: How to Spot Questionable Telehealth Services

The popularity of GLP-1 weight loss medications has, unfortunately, attracted some bad actors. Here’s what to watch out for:

🚩 Guaranteed Prescriptions Without Evaluation

Legitimate healthcare requires individualized assessment. Be wary of any service that promises you’ll definitely get a prescription before you’ve even spoken to a provider. Responsible platforms will be upfront that prescriptions are contingent on meeting clinical criteria and having no contraindications.

🚩 Compounded or ‘Generic’ Versions

In 2025, the FDA took significant enforcement action against compounding pharmacies making copycat versions of semaglutide. After declaring the shortage over in May 2025, FDA essentially banned routine compounding of semaglutide for weight loss. Why? Compounded versions bypass FDA oversight for manufacturing quality, sterility, and dosing accuracy—creating potential safety risks.

Some telehealth companies shifted to compounded tirzepatide or experimental alternatives when the semaglutide ban hit. Be extremely cautious. While there may be limited legitimate circumstances for compounding (e.g., a patient with a specific allergy to an inactive ingredient), most compounded GLP-1s today are cutting corners on quality to offer cheaper prices.

Stick with FDA-approved, brand-name medications: Wegovy, Ozempic, Mounjaro, and Zepbound dispensed through licensed U.S. pharmacies.

🚩 No Follow-Up or Monitoring

Real medical care doesn’t stop after the first prescription. Any telehealth service that doesn’t schedule follow-up appointments (or makes them optional) is not providing safe, responsible care. These medications have side effects that need monitoring, and dose adjustments are often necessary for optimal results.

🚩 Unclear Provider Credentials

You should always know who you’re seeing. Legitimate platforms will display provider credentials, license numbers, and which states they’re authorized to practice in. If the provider’s qualifications are vague or hidden, that’s a major red flag.

🚩 Pressure Tactics or Unrealistic Promises

Weight loss is a gradual process, even with these powerful medications. Be skeptical of claims like ‘lose 30 pounds in 30 days’ or high-pressure sales tactics pushing you to commit immediately. Good providers will set realistic expectations: typical weight loss is 1-2 pounds per week, with results building over months, not days.

🚩 No Discussion of Risks or Alternatives

Informed consent is not just a legal requirement—it’s an ethical one. Your provider should discuss potential side effects (nausea, vomiting, diarrhea, constipation, gallbladder issues, and rare but serious risks like pancreatitis or thyroid tumors), contraindications, and alternatives to medication (lifestyle-based programs, other medication options, or bariatric surgery for severe obesity).

How Klarity Health Approaches Telehealth Weight Loss Care

At Klarity Health, we believe weight management support should be accessible, transparent, and clinically sound. Here’s what sets our approach apart:

Licensed Providers in Your State: We only connect you with healthcare providers who are fully licensed and credentialed to practice where you live. Whether it’s an MD, DO, NP, or PA, you can trust that your provider meets all regulatory requirements for your state.

Comprehensive Evaluation: Our consultations aren’t rushed checkbox exercises. Providers take the time to understand your health history, discuss your goals, and determine whether GLP-1 medications are the right fit for you—or if another approach might be better.

Transparent Pricing: We accept both insurance and cash pay, and we’re upfront about costs. No surprise bills or hidden fees. If your insurance covers weight loss medications, we’ll work with your plan. If you’re paying out of pocket, you’ll know the costs before committing.

Ongoing Support: Weight loss is a journey, not a one-time transaction. We schedule regular follow-ups to monitor your progress, adjust treatment as needed, and provide the encouragement and accountability that makes long-term success possible.

Evidence-Based Care: Our providers stay current with the latest research and FDA guidance. We prescribe FDA-approved medications through licensed pharmacies—no compounded alternatives or workarounds that compromise safety.

Flexible Appointments: Provider availability is key to staying on track. We offer evening and weekend appointments to fit your schedule, and virtual visits mean you won’t lose work time sitting in a waiting room.

If you’ve been struggling with weight and wondering whether prescription medication might help, a Klarity consultation can provide clarity (pun intended). We’ll give you honest guidance about whether you’re a good candidate, what to expect, and how to maximize your chances of success.

Common Questions About Telehealth Weight Loss Treatment

Do I need to see a provider in person first?
In most states, no—the entire process can be done via telehealth. However, a few states (like Arkansas, Georgia, Texas, Mississippi, South Carolina, North Dakota, Delaware, New Jersey, and Virginia) require or strongly encourage an initial in-person examination. Your telehealth provider will let you know if this applies to you and can often coordinate with a local clinic for the physical exam component.

What if I move to a different state during treatment?
You’ll need to work with a provider licensed in your new state. Fortunately, many telehealth platforms (including Klarity) have providers in multiple states. You may be able to continue with the same platform but will likely transition to a different prescriber. Interstate compacts have made this easier for MDs and NPs, but it’s still important to notify your provider before relocating.

How long will I need to take these medications?
GLP-1 medications are intended for long-term, potentially indefinite use. They’re treating a chronic condition (obesity), not providing a quick fix. Most people regain weight if they stop the medication without other interventions. Your provider will discuss maintenance strategies, and some patients do successfully transition off medication after reaching their goal weight and establishing strong lifestyle habits—but this should be done under medical supervision.

Will my insurance cover it?
Coverage is expanding rapidly as insurers recognize the health benefits of treating obesity (reducing diabetes risk, improving cardiovascular health, etc.). Many commercial plans now cover GLP-1s for weight loss with prior authorization. Medicare historically hasn’t covered weight loss drugs, but advocacy efforts are ongoing. Medicaid coverage varies by state. Your telehealth provider can help you navigate insurance approval or discuss cash-pay options if coverage isn’t available.

What if I don’t lose weight on the medication?
Not everyone responds the same way to these medications. If you haven’t lost at least 5% of your body weight after 12-16 weeks at the full dose, your provider should reassess. This might mean trying a different medication (e.g., switching from semaglutide to tirzepatide), investigating underlying causes of weight loss resistance (thyroid issues, medications that promote weight gain, sleep disorders), or considering alternative approaches.

Can I get these medications if I just want to lose 10-15 pounds for cosmetic reasons?
Probably not through legitimate medical channels. These are powerful medications with real side effects, and they’re intended for people with medical obesity or significant weight-related health problems. If your BMI is under 27 and you don’t have comorbidities, responsible providers will recommend lifestyle-based approaches instead. Using prescription medications for purely cosmetic weight loss when you’re at a healthy weight is not medically appropriate and most providers won’t prescribe in those circumstances.

The Future of Telehealth Weight Loss Treatment

Telehealth for weight management isn’t going away—it’s becoming the standard of care for many patients. Here’s what we’re watching in 2025 and beyond:

Regulatory Evolution: The DEA’s temporary telehealth flexibilities for controlled substances are set to expire December 31, 2025, but all signs point to an extension or permanent rule that maintains current access. For GLP-1s specifically (which aren’t controlled), the regulatory environment is stable and supportive.

New Medications on the Horizon: Pharmaceutical companies are developing next-generation obesity medications, including oral GLP-1 agonists (no more injections), triple-action incretin mimetics, and longer-acting formulations. Telehealth will be the ideal delivery model for these new therapies.

Broader Insurance Coverage: As evidence mounts that treating obesity reduces long-term healthcare costs (by preventing diabetes, heart disease, and other expensive conditions), more insurers are covering anti-obesity medications. We expect this trend to accelerate.

Integration with Lifestyle Programs: The most effective approach combines medication with behavior change. Telehealth platforms are increasingly offering comprehensive programs that pair medication management with nutrition coaching, fitness guidance, and mental health support—all delivered virtually.

State Practice Authority Expansions: More states are granting NPs full independent practice authority (34 states plus DC as of 2025, up from just a handful a decade ago). This expands the pool of qualified telehealth providers and can improve access, especially in underserved areas.

Taking the First Step

If you’re ready to explore whether prescription weight loss medication might be right for you, telehealth offers an accessible, convenient pathway—without sacrificing quality of care.

What to do next:

1. Check your eligibility: Calculate your BMI and consider whether you have weight-related health conditions. If your BMI is ≥30 or ≥27 with comorbidities, you may be a candidate.

2. Research reputable providers: Look for telehealth platforms with licensed providers, transparent pricing, and clear follow-up care. Read reviews and verify the platform’s legitimacy.

3. Prepare for your consultation: Gather your medical history, current medications, and questions. Be honest about your weight loss goals and any previous attempts—your provider needs accurate information to guide you safely.

4. Schedule an appointment: Many telehealth platforms offer appointments within days, not weeks. Virtual visits can often be scheduled during lunch breaks or evenings.

5. Commit to the process: If you receive a prescription, remember that medication is just one tool. Your success will depend on consistent use, following up with your provider, and making sustainable lifestyle changes.

At Klarity Health, we’re here to support you through every step of your weight loss journey. Our providers understand the challenges of managing weight and the profound impact it can have on your overall health and quality of life. We offer judgment-free care focused on helping you achieve realistic, sustainable results.

Ready to get started? Book a consultation with a Klarity provider today to discuss whether telehealth weight loss treatment is right for you. With flexible scheduling, transparent pricing, and providers who truly listen, we’re making quality obesity care accessible to more people than ever before.

Citations and Sources

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – Drug Enforcement Administration official announcement, November 15, 2024. www.dea.gov

2. COVID-era telehealth prescribing extended through 2025 – Axios News, November 18, 2024. www.axios.com

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery Legal Analysis, November 18, 2024. www.mwe.com

4. Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs – Goodwin Procter Law Firm Client Alert, March 27, 2024. www.goodwinlaw.com

5. Telehealth’s GLP-1 Boom: Balancing Obesity Care with HIPAA and State Consumer Privacy Laws – Reuters Legal Industry Analysis, August 20, 2025. www.reuters.com

Research Currency Statement: This article was researched and verified as of December 17, 2025. Federal telehealth rules for controlled substances remain temporary through December 31, 2025, with extension anticipated. State regulations are subject to change; readers should verify current requirements in their specific state. All clinical information aligns with current FDA guidance and medical standards of care.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid